Lisanti Capital Growth LLC Grows Stake in Tarsus Pharmaceuticals, Inc. $TARS

Lisanti Capital Growth LLC increased its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 49.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 64,341 shares of the company’s stock after acquiring an additional 21,330 shares during the period. Tarsus Pharmaceuticals makes up approximately 1.2% of Lisanti Capital Growth LLC’s investment portfolio, making the stock its 29th biggest position. Lisanti Capital Growth LLC’s holdings in Tarsus Pharmaceuticals were worth $5,268,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Comerica Bank grew its position in Tarsus Pharmaceuticals by 470.0% in the fourth quarter. Comerica Bank now owns 855 shares of the company’s stock worth $70,000 after acquiring an additional 705 shares in the last quarter. Leonteq Securities AG purchased a new position in Tarsus Pharmaceuticals in the fourth quarter worth about $164,000. Mirae Asset Global Investments Co. Ltd. grew its position in Tarsus Pharmaceuticals by 26.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,063 shares of the company’s stock worth $169,000 after acquiring an additional 431 shares in the last quarter. Osaic Holdings Inc. grew its position in Tarsus Pharmaceuticals by 779.1% in the second quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock worth $113,000 after acquiring an additional 2,462 shares in the last quarter. Finally, Valeo Financial Advisors LLC purchased a new position in Tarsus Pharmaceuticals in the third quarter worth about $209,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Down 1.9%

Shares of NASDAQ:TARS opened at $62.26 on Friday. Tarsus Pharmaceuticals, Inc. has a 1 year low of $38.51 and a 1 year high of $85.25. The business has a 50 day simple moving average of $66.07 and a two-hundred day simple moving average of $71.38. The firm has a market capitalization of $2.68 billion, a PE ratio of -54.61 and a beta of 0.52. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.74 and a quick ratio of 3.71.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%.The business had revenue of $162.05 million during the quarter, compared to analyst estimates of $149.60 million. On average, equities analysts predict that Tarsus Pharmaceuticals, Inc. will post -0.59 EPS for the current year.

Insiders Place Their Bets

In other Tarsus Pharmaceuticals news, Director William J. Phd Link sold 12,500 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $68.79, for a total transaction of $859,875.00. Following the completion of the transaction, the director owned 116,332 shares in the company, valued at $8,002,478.28. The trade was a 9.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Bryan Wahl sold 4,231 shares of the business’s stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total value of $283,477.00. Following the transaction, the general counsel owned 63,959 shares of the company’s stock, valued at $4,285,253. This trade represents a 6.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 79,391 shares of company stock worth $5,432,035 over the last three months. 9.64% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Oppenheimer assumed coverage on Tarsus Pharmaceuticals in a research report on Friday, April 24th. They issued an “outperform” rating and a $98.00 price target for the company. Wall Street Zen lowered Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $68.00 price target on shares of Tarsus Pharmaceuticals in a research report on Thursday, February 5th. Lifesci Capital upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, March 16th. Finally, Zacks Research lowered Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $90.67.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.